Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18205
Country/Region: Kenya
Year: 2016
Main Partner: University of Maryland
Main Partner Program: University of Maryland Baltimore
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $6,223,928 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,075,877
Care: TB/HIV (HVTB) $244,284
Care: Pediatric Care and Support (PDCS) $342,937
Testing: HIV Testing and Counseling (HVCT) $645,600
Sexual Prevention: Other Sexual Prevention (HVOP) $1,082,000
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $837,483
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $350,342
Treatment: Adult Treatment (HTXS) $1,287,410
Treatment: Pediatric Treatment (PDTX) $357,995
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: 10-14 Female 2017 2,138
GEND_GBV Age/Sex: 15-19 Female 2017 7,952
GEND_GBV Age/Sex: 20-24 Female 2017 7,957
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 2,151
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 10,973
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 7,119
GEND_GBV Number of people receiving post-GBV care 2017 18,092
GEND_GBV Sum of Age/Sex Disaggregates 2017 2,138
HTS_TST Age/sex: <1 2017 46
HTS_TST Age/sex: <1 2017 610
HTS_TST Age/sex: 1-9 2017 502
HTS_TST Age/sex: 1-9 2017 131,236
HTS_TST Age/sex: 10-14 Female 2017 124
HTS_TST Age/sex: 10-14 Female 2017 22,660
HTS_TST Age/sex: 10-14 Male 2017 175
HTS_TST Age/sex: 10-14 Male 2017 14,366
HTS_TST Age/sex: 15-19 Female 2017 1,794
HTS_TST Age/sex: 15-19 Female 2017 16,369
HTS_TST Age/sex: 15-19 Male 2017 2,593
HTS_TST Age/sex: 15-19 Male 2017 8,875
HTS_TST Age/sex: 20-24 Female 2017 7,197
HTS_TST Age/sex: 20-24 Female 2017 57,388
HTS_TST Age/sex: 20-24 Male 2017 10,381
HTS_TST Age/sex: 20-24 Male 2017 28,775
HTS_TST Age/sex: 25-49 Female 2017 18,575
HTS_TST Age/sex: 25-49 Female 2017 125,835
HTS_TST Age/sex: 25-49 Male 2017 26,788
HTS_TST Age/sex: 25-49 Male 2017 60,433
HTS_TST Age/sex: 50+ Female 2017 1,095
HTS_TST Age/sex: 50+ Female 2017 11,548
HTS_TST Age/sex: 50+ Male 2017 1,580
HTS_TST Age/sex: 50+ Male 2017 7,590
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 306
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 154,749
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 95
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 85,432
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 19,534
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 251,285
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 5,704
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 116,614
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 70,858
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 608,965
HTS_TST Service Delivery Point (Facility): Index testing 2017 967
HTS_TST Service Delivery Point (Facility): Index testing 2017 9,031
HTS_TST Service Delivery Point (Facility): Inpatient 2017 4,005
HTS_TST Service Delivery Point (Facility): Inpatient 2017 36,264
HTS_TST Service Delivery Point (Facility): Other PITC 2017 528
HTS_TST Service Delivery Point (Facility): Other PITC 2017 4,921
HTS_TST Service Delivery Point (Facility): Outpatient 2017 41,677
HTS_TST Service Delivery Point (Facility): Outpatient 2017 369,758
HTS_TST Service Delivery Point (Facility): Pediatric 2017 693
HTS_TST Service Delivery Point (Facility): Pediatric 2017 6,417
HTS_TST Service Delivery Point (Facility): PMTCT 2017 4,005
HTS_TST Service Delivery Point (Facility): PMTCT 2017 36,284
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 146
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,367
HTS_TST Service Delivery Point (Facility): VCT 2017 17,274
HTS_TST Service Delivery Point (Facility): VCT 2017 141,294
HTS_TST Service Delivery Point (Facility): VMMC 2017 1,558
HTS_TST Service Delivery Point (Facility): VMMC 2017 2,771
HTS_TST Sum of Age/Sex disaggregates 2017 70,302
HTS_TST Sum of Age/Sex disaggregates 2017 353,839
HTS_TST Sum of Aggregated Age/Sex <15 2017 401
HTS_TST Sum of Aggregated Age/Sex <15 2017 240,181
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 25,238
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 367,899
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 25,639
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 608,080
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 11
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 91
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 4
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 39
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 57
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 241
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 17
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 91
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 328
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,231
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 109
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 487
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 1,108
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 4,619
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 411
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,880
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 86
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 585
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 32
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 266
HTS_TST_POS Test Result by Age: Positive: <1 2017 2
HTS_TST_POS Test Result by Age: Positive: <1 2017 20
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 16
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 404
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 25
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,036
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 9
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,089
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 1,602
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 16,123
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 550
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 5,782
OVC_SERV Age/Sex: 18+ Female 2017 10,702
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 4,591
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 15,293
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14 2017 581
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17 2017 2,108
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 2017 889
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+ 2017 1,799
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2017 702
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2017 3,570
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 2017 587
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female <1 2017 1,155
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9 2017 1,456
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14 2017 2,056
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 2017 1,662
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 2017 1,182
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24 2017 10,182
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Male 25+ 2017 10,182
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1 2017 1,044
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 2017 2,738
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14 2017 580
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 2017 595
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 2017 595
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9 2017 578
OVC_SERV Sum of Age/Sex disaggregates 2017 10,702
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,681
PMTCT_ART New on ART 2017 941
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 118,093
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,164
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 968
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 94
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 54
PMTCT_EID Sum of Infant Age disaggregates 2017 3,132
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 254
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 1,381
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 8,880
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 18,898
PMTCT_STAT By: Known positives at entry 2017 3,493
PMTCT_STAT By: Number of new positives identified 2017 1,444
PMTCT_STAT Number of new ANC and L&D clients 2017 118,093
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 118,093
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 2
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 24
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 199
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 1,151
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 230
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 4
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 66
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 393
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 75
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,937
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 256
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 1,371
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 8,875
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 18,867
PP_PREV Aggregated Age/sex: <15 Female 2017 1,777
PP_PREV Aggregated Age/sex: <15 Male 2017 986
PP_PREV Aggregated Age/sex: 15+ Female 2017 6,473
PP_PREV Aggregated Age/sex: 15+ Male 2017 186
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 9,989
PP_PREV Total number of people in the target population 2017 59,911
PrEP_NEW Female 15-19 2017 1,655
PrEP_NEW Female 20-24 2017 7,169
PrEP_NEW Number of individuals who have received antiretroviral preexposure 2017 8,777
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 35
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 681
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 106
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 934
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,759
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,759
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 15,536
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 24
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 15,836
TB_SCREENDX Screen Result: Screened Positive for TB 2017 17,581
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 56,367
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 23,211
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,059
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 3,921
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 87,882
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 175
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,565
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 291
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,044
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 6,080
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 6,080
TX_CURR Age/Sex: <1 2017 102
TX_CURR Age/Sex: <1-9 2017 5,259
TX_CURR Age/Sex: 10-14 Female 2017 1,307
TX_CURR Age/Sex: 10-14 Male 2017 1,308
TX_CURR Age/Sex: 15-19 Female 2017 1,262
TX_CURR Age/Sex: 15-19 Male 2017 527
TX_CURR Age/Sex: 20-24 Female 2017 4,989
TX_CURR Age/Sex: 20-24 Male 2017 1,127
TX_CURR Age/Sex: 25-49 Female 2017 41,994
TX_CURR Age/Sex: 25-49 Male 2017 16,138
TX_CURR Age/Sex: 50+ Female 2017 8,307
TX_CURR Age/Sex: 50+ Male 2017 5,462
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,061
TX_CURR Aggregated Age/Sex: <15 Male 2017 3,913
TX_CURR Aggregated Age/Sex: 15+ Female 2017 56,656
TX_CURR Aggregated Age/Sex: 15+ Male 2017 23,250
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 87,882
TX_CURR Sum of age/sex disaggregates 2017 1,789
TX_CURR Sum of Aggregated Age/Sex <15 2017 7,974
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 79,906
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 87,880
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 707
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 632
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 14,085
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 6,161
TX_NEW By Age/Sex: <1 2017 104
TX_NEW By Age/Sex: 1-9 2017 772
TX_NEW By Age/Sex: 10-14 Female 2017 253
TX_NEW By Age/Sex: 10-14 Male 2017 211
TX_NEW By Age/Sex: 15-19 Female 2017 316
TX_NEW By Age/Sex: 15-19 Male 2017 104
TX_NEW By Age/Sex: 20-24 Female 2017 1,610
TX_NEW By Age/Sex: 20-24 Male 2017 448
TX_NEW By Age/Sex: 25-49 Female 2017 10,427
TX_NEW By Age/Sex: 25-49 Male 2017 4,460
TX_NEW By Age/Sex: 50+ Female 2017 1,731
TX_NEW By Age/Sex: 50+ Male 2017 1,248
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 21,684
TX_NEW Sum of Age/Sex disaggregates 2017 20,808
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 21,585
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 77,924
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 79,438
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 3,726
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 3,577
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 51,146
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 20,972
TX_PVLS Numerator: Indication: Routine 2017 79,111
TX_PVLS Numerator: Indication: Targeted 2017 327
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,651
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,528
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 50,237
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 20,542
TX_PVLS_den Denominator: Indication: Routine 2017 77,898
TX_PVLS_den Denominator: Indication: Targeted 2017 23
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 99
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 716
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 235
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 198
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 284
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 98
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,449
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 401
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,183
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,978
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,552
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,125
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 656
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 592
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12,468
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,603
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 19,319
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 21,684
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 104
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 772
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 253
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 211
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 316
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 104
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,609
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 448
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10,428
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,464
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,727
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,244
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 707
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 633
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14,085
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,259
Cross Cutting Budget Categories and Known Amounts Total: $754,836
Gender: Gender Based Violence (GBV) $377,418
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $377,418
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation